Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Satoko Morishima, MD PhD, Kenji Ishitsuka, MD PhD, Koji Izutsu, MD PhD, Shigeru Kusumoto, MD PhD, Junya Makiyama, MD PhD, Atae Utsunomiya, MD, Kisato Nosaka, MD PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD PhD, Nobuhiko Yamauchi, MD, Kazushi Araki, DVM, PhD, Nobuaki Adachi, PhD, Tomonari Yamashita, Ryo Atsumi, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD

Blood (2019) 134 (Supplement_1): 4025.

https://doi.org/10.1182/blood-2019-125507

Published: 2019

Journal Articles

DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation

Blood (2018) 132 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2018-99-113379

Published: 2018

Journal Articles

EZH1/2, SWI/SNF, and MLL2 Dependent Heterochromatin Formation and Abnormal Transcriptome in Hematological Malignancies

Makoto Yamagishi, PhD, Dai Fujikawa, PhD, Makoto Hori, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Seiichiro Kobayashi, MD, PhD, Masako Iwanaga, MD PhD MPH, Atae Utsunomiya, MD, Seiji Okada, MD, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD, Kazushi Araki, D.V.M., PhD, Toshiki Watanabe, MD, PhD, Kaoru Uchimaru, MD, PhD

Blood (2017) 130 (Supplement 1): 1200.

https://doi.org/10.1182/blood.V130.Suppl_1.1200.1200

Published: 2017

Journal Articles

Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

Daisuke Honma, PhD, Nobuaki Adachi, PhD, Osamu Kanno, PhD, Jun Watanabe, Makoto Hirasawa, Emi Nosaka, Machiko Shiroishi, Takeshi Takizawa, Isao Yasumatsu, Takao Horiuchi, PhD, Akira Nakao, PhD, Keisuke Suzuki, Tomonori Yamasaki, Katsuyoshi Nakajima, Miho Hayakawa, Takanori Yamazaki, Kazushi Araki, D.V.M., PhD, Kosaku Fujiwara, PhD

Blood (2017) 130 (Supplement 1): 2073.

https://doi.org/10.1182/blood.V130.Suppl_1.2073.2073

Published: 2017

Journal Articles

Population Pharmacokinetic and Exposure-Response Modeling for the EZH1/2 Dual Inhibitor DS-3201b in Patients with Non-Hodgkin Lymphomas

Ryo Atsumi, PhD, Satoshi Yoshiba, Dai Maruyama, MD PhD, Kensei Tobinai, MD PhD, Takashi Ishida, MD PhD, Kenji Ishitsuka, MD PhD, Yoshitaka Imaizumi, MD PhD, Shogo Takeuchi, MD, Kunihiro Tsukasaki, MD PhD, Nobuaki Adachi, PhD, Sumiaki Fujitani, MSc, Masaya Tachibana, PhD, Kazutaka Yoshihara, Hitoshi Ishizuka, PhD

Blood (2017) 130 (Supplement 1): 2544.

https://doi.org/10.1182/blood.V130.Suppl_1.2544.2544

Published: 2017

Journal Articles

Development and Molecular Analysis of Synthetic Lethality By Targeting EZH1 and EZH2 in Non-Hodgkin Lymphomas

Makoto Yamagishi, PhD, Makoto Hori, Dai Fujikawa, PhD, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Takeo Ohsugi, D.V.M., PhD, Kazumi Nakano, PhD, Makoto Nakashima, Seiichiro Kobayashi, MD, PhD, Masako Iwanaga, MD, PhD, Atae Utsunomiya, MD, PhD, Seiji Okada, MD, PhD, Kunihiro Tsukasaki, MD, Kensei Tobinai, MD, PhD, Kazushi Araki, D.V.M., PhD, Toshiki Watanabe, MD, PhD, Kaoru Uchimaru, MD PhD

Blood (2016) 128 (22): 462.

https://doi.org/10.1182/blood.V128.22.462.462

Published: 2016

Journal Articles

Polycomb-Dependent Epigenetic Landscape in Adult T Cell Leukemia (ATL); Providing Proof of Concept for Targeting EZH1/2 to Selectively Eliminate the HTLV-1 Infected Population

Makoto Yamagishi, PhD, Dai Fujikawa, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Shota Nakagawa, Makoto Hori, Naoya Kurokawa, Ai Soejima, Kazumi Nakano, PhD, Tadanori Yamochi, PhD, Makoto Nakashima, Seiichiro Kobayashi, MD, PhD, Yuetsu Tanaka, MD, PhD, Masako Iwanaga, MD, PhD, Atae Utsunomiya, MD, PhD, Kaoru Uchimaru, MD, PhD, Kunihiro Tsukasaki, MD, PhD, Kazushi Araki, D.V.M., PhD, Toshiki Watanabe, MD, PhD

Blood (2015) 126 (23): 572.

https://doi.org/10.1182/blood.V126.23.572.572

Published: 2015

Journal Articles

Novel Leukemia Stem Cell-Targeted Therapy for Acute Myeloid Leukemia Based on Dual Inhibition of Ezh1/Ezh2

Shuhei Fujita, MD BS, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Kazushi Araki, D.V.M., PhD, Emi Takamatsu, PhD, Kazumasa Aoyama, PhD, Atsushi Iwama, MD PhD, Issay Kitabayashi, PhD

Blood (2015) 126 (23): 457.

https://doi.org/10.1182/blood.V126.23.457.457

Published: 2015

NARROW

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation

EZH1/2, SWI/SNF, and MLL2 Dependent Heterochromatin Formation and Abnormal Transcriptome in Hematological Malignancies

Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

Population Pharmacokinetic and Exposure-Response Modeling for the EZH1/2 Dual Inhibitor DS-3201b in Patients with Non-Hodgkin Lymphomas

Development and Molecular Analysis of Synthetic Lethality By Targeting EZH1 and EZH2 in Non-Hodgkin Lymphomas

Polycomb-Dependent Epigenetic Landscape in Adult T Cell Leukemia (ATL); Providing Proof of Concept for Targeting EZH1/2 to Selectively Eliminate the HTLV-1 Infected Population

Novel Leukemia Stem Cell-Targeted Therapy for Acute Myeloid Leukemia Based on Dual Inhibition of Ezh1/Ezh2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only